Alexa Fluor® 700 anti-mouse CD86

Antibodies Single
Sony
PO3
Flow Cytometry
Rat IgG2b, κ
Mouse
BALB/c mouse B leukemia cell line BCL1
100 µg
1125610
$226.00

Description

CD86 is an 80 kD immunoglobulin superfamily member, also known as B7-2, B70, and Ly-58. CD86 is expressed on activated B and T cells, macrophages, dendritic cells and astrocytes. CD86 along with CD80 are the ligands of CD28 and CD152 (CTLA-4). CD86 is expressed earlier in the immune response than CD80. CD86 has also been shown to be involved in immunoglobulin class-switching and triggering of NK cell-mediated cytotoxicity. CD86 binds to CD28 to transduce co-stimulatory signals for T cell activation, proliferation, and cytokine production. CD86 can also bind to CD152, also known as CTLA-4, to deliver an inhibitory signal to T cells. The PO3 antibody has been shown to block autoantibody production in vivo and inhibit T cell activation in vitro.

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. The suggested use of this reagent is ≤1.0 microg per million cells in 100 microL volume. It is highly recommended that the reagent be titrated for optimal performance for each application.

* Alexa Fluor® 700 has a maximum emission of 719 nm when it is excited at 633 nm / 635 nm. Prior to using Alexa Fluor® 700 conjugate for flow cytometric analysis, please verify your flow cytometer's capability of exciting and detecting the fluorochrome.

References

1. Nakajima A, et al. 1995. Eur. J. Immunol. 25:3060.
2. Nuriya S, et al. 1996. Int. Immunol. 8:917.
3. Kasprowicz DJ, et al. 2000. J. Immunol. 165:680.
4. Saito K, et al. 1998. J. Immunol. 160:4225.
5. Nakajima A, et al. 1998. J. Immunol. 161:1901.
6. Ma XT, et al. 2006. Cancer Research 66:1169.
7. Lawson BR, et al. 2007. J. Immunol. 178:5366.
8. Bhatnagar S and Schorey JS. 2007. J. Biol. Chem. doi:10.1074/jbc.M702277200.
9. Giroux M, et al. 2007. J. Immunol. 179:4492.
10. Luger R. et al. 2013. PLoS One. 8:e54879. PubMed.
11. Mayer E, et al. 2013. Int Immunopharmacol. 15:638. PubMed.